文献速递肿瘤 PET/CT核素与放射性配体治疗

抗雄激素治疗状态影响前列腺癌患者68Ga-PSMA-HBED-CC PET生物分布

Antihormonal-Treatment Status Affects 68Ga-PSMA-HBED-CC PET Biodistribution in Patients with Prostate Cancer.
PubMed 文献 · J Nucl Med · 2023-09-21

回顾性纳入112例经组织学证实的前列腺癌男性患者,56例接受促性腺激素释放激素干扰性雄激素剥夺治疗(ADT),56例无ADT史作为对照,比较68Ga-PSMA-HBED-CC PET/CT中生理性PSMA表达器官的摄取。ADT组肾脏、肝脏、脾脏和唾液腺的PSMA摄取均低于对照组,多因素分析显示ADT与上述器官摄取降低相关,肾小球滤过率较高与肾脏SUVmean较高相关。作者认为ADT可能系统性调节PSMA表达,可能对PSMA放射性配体治疗的优化策略有启示。

要点

  • ADT组肾脏SUVmean较对照组降低7.89(95%CI -10.73至-5.04,P<0.001)。
  • ADT组肝脏、脾脏、唾液腺摄取亦低于对照组,多因素分析结果一致。
  • 肾小球滤过率较高与肾脏SUVmean较高相关(β=0.16,95%CI 0.05至0.26,P=0.0034)。

核心结论

  • 作者认为这些发现提示ADT系统性调节PSMA表达,可能对PSMA放射性配体治疗的优化治疗和减少副作用的策略有启示,尤其是使用更强效的225Ac标记PSMA偶联物的治疗。

研究设计与样本

  • 回顾性纳入2015年11月至2021年7月在维也纳医科大学接受68Ga-PSMA-HBED-CC(68Ga-PSMA-11)PET/CT且ADT状态已知的112例经组织学证实的前列腺癌男性患者。
  • 56例在显像时接受促性腺激素释放激素干扰性ADT(ADT组),56例无ADT史作为对照组。
  • 勾画生理性PSMA表达器官(唾液腺、肾脏、肝脏、脾脏),按数据分布比较摄取,并用多因素回归分析肾脏、肝脏、脾脏和唾液腺摄取与代谢肿瘤体积、肾小球滤过率、ADT状态的关系。

主要发现

  • ADT组肾脏SUVmean较对照组降低7.89(Δ[ADT-对照]=-7.89;95%CI -10.73至-5.04;P<0.001)。
  • ADT组肝脏SUVpeak较对照组降低2.3(Δ[ADT-对照]=-2.3;95%CI -5.72至-0.93;P=0.003)。
  • ADT组脾脏SUVpeak较对照组降低1.27(Δ[ADT-对照]=-1.27;95%CI -3.61至-0.16;P=0.033)。
  • ADT组唾液腺SUVmean较对照组降低1.04(Δ[ADT-对照]=-1.04;95%CI -2.48至-0.13;P=0.027)。
  • 多因素分析中ADT与肾脏SUVmean(β=-7.95;95%CI -11.06至-4.84;P<0.0001)、肝脏SUVpeak(β=-7.85;95%CI -11.78至-3.91;P<0.0001)、脾脏SUVpeak(β=-5.83;95%CI -9.95至-1.7;P=0.006)、唾液腺SUVmean(β=-1.47;95%CI -2.76至-0.17;P=0.027)摄取降低相关。

关键数值与推荐

  • ADT组肾脏SUVmean较对照组降低7.89(95%CI -10.73至-5.04,P<0.001)。
  • ADT组肝脏SUVpeak较对照组降低2.3(95%CI -5.72至-0.93,P=0.003)。
  • ADT组脾脏SUVpeak较对照组降低1.27(95%CI -3.61至-0.16,P=0.033)。
  • ADT组唾液腺SUVmean较对照组降低1.04(95%CI -2.48至-0.13,P=0.027)。
  • 肾小球滤过率较高与肾脏SUVmean较高相关(β=0.16;95%CI 0.05至0.26;P=0.0034)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Androgen deprivation therapy (ADT) is known to influence the prostate-specific membrane antigen (PSMA) expression of prostate cancer, potentially complicating the interpretation of PSMA ligand PET findings and affecting PSMA radioligand therapy. However, the impact of ADT on PSMA ligand biodistribution in nontumorous organs is not well understood. Methods: Men (n = 112) with histologically proven prostate cancer who underwent 68Ga-PSMA-HBED-CC (68Ga-PSMA-11) PET/CT between November 2015 and July 2021 at the Medical University Vienna with known ADT status were retrospectively recruited. Fifty-six patients were on gonadotropin-releasing hormone-interfering ADT at the time of imaging (ADT group), whereas 56 patients with no history of ADT served as a control group. Physiologically PSMA-expressing organs (salivary glands, kidneys, liver, and spleen) were delineated, and their uptake was compared according to their data distributions. Multivariate regression analysis assessed the relationship between renal, hepatic, splenic, and salivary gland uptake and the explanatory variables metabolic tumor volume, glomerular filtration rate, and ADT status. Results: ADT was associated with lower levels of PSMA uptake in the kidneys (SUVmean: Δ[ADT - control] = -7.89; 95% CI, -10.73 to -5.04; P < 0.001), liver (SUVpeak: Δ[ADT - control] = -2.3; 95% CI, -5.72 to -0.93; P = 0.003), spleen (SUVpeak: Δ[ADT - control] = -1.27; 95% CI, -3.61 to -0.16; P = 0.033), and salivary glands (SUVmean: Δ[ADT - control] = -1.04; 95% CI, -2.48 to -0.13; P = 0.027). In a multivariate analysis, ADT was found to be associated with lower renal (SUVmean: β = -7.95; 95% CI, -11.06 to -4.84; P < 0.0001), hepatic (SUVpeak: β = -7.85; 95% CI, -11.78 to -3.91; P < 0.0001), splenic (SUVpeak: β = -5.83; 95% CI, -9.95 to -1.7; P = 0.006), and salivary gland (SUVmean: β = -1.47; 95% CI, -2.76 to -0.17; P = 0.027) uptake. A higher glomerular filtration rate was associated with a higher renal SUVmean (β = 0.16; 95% CI, 0.05 to 0.26; P = 0.0034). Conclusion: These findings suggest that ADT systemically modulates PSMA expression, which may have implications for treatment-optimizing and side-effect-minimizing strategies for PSMA radioligand therapies, particularly those using more potent 225Ac-labeled PSMA conjugates.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Kluge K, Haberl D, Einspieler H, et al. Antihormonal-Treatment Status Affects 68Ga-PSMA-HBED-CC PET Biodistribution in Patients with Prostate Cancer. J Nucl Med. 2023. PMID: 37734840. doi:10.2967/jnumed.123.265980

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。